share_log
Moomoo 24/7 ·  Apr 9 16:44
Fusion Pharmaceuticals Hightlights Presentation Of Interim Data From Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 At The AACR Annual Meeting 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment